Valuing CEL-SCI Corporation’s Pipeline: A VC Approach

zsinkala , , , ,

Evaluation of CEL-SCI Corporation (CVM) Pipeline Using Venture Capital Valuation Method

Evaluating CEL-SCI Corporation (CVM) using the Venture Capital Valuation Method involves estimating the potential value of the company’s product pipeline, particularly its leading product Multikine, and applying basic math to project its future value. This method is useful for high-risk, high-reward ventures like biotech companies where product success is uncertain.

1. Step 1: Estimate Potential Market Size

To evaluate CEL-SCI’s Multikine, we start by estimating the total addressable market (TAM) for the product. Multikine targets head and neck cancer, so let’s calculate the market size.

  • Total Addressable Market (TAM): According to cancer statistics, about 900,000 new head and neck cancer cases are diagnosed globally each year.
  • Let’s assume that Multikine targets 10% of these cases (a reasonable penetration rate).
  • The average cost of treatment for advanced immunotherapies is estimated at $100,000 per patient.

Using these estimates, the market size Multikine could target is:

TAM = 900,000 × 10% × 100,000 = 90,000 × 100,000 = 9 billion USD per year

2. Step 2: Estimate Potential Revenue

Next, we calculate CEL-SCI’s potential revenue from Multikine, assuming it captures a portion of this market over time.

  • Let’s assume CEL-SCI captures 20% of the target market, which is reasonable for a successful cancer drug.

So, the potential revenue is:

Potential Revenue = 9 billion × 20% = 1.8 billion USD per year

3. Step 3: Estimate Profit Margin

Biotech companies typically have high profit margins after the initial R&D and manufacturing scale-up phase. For a successful immunotherapy, a profit margin of 30% is a reasonable assumption.

So, the potential profit for CEL-SCI from Multikine can be calculated as:

Profit = 1.8 billion × 30% = 540 million USD per year

4. Step 4: Estimate Time to Market

  • Multikine is currently in the regulatory approval stage. If approved, it will take time to scale up and reach full market penetration.
  • Assume that it will take 5 years to reach peak sales and market share.

5. Step 5: Apply Discount Rate (Risk Adjustment)

The biotech industry is high-risk, and there’s always a chance that the product may not be approved or commercially viable. We’ll apply a discount rate to account for this risk.

  • A discount rate of 40% is commonly used for high-risk biotech ventures, reflecting the uncertainty of clinical trial success and market adoption.

6. Step 6: Calculate the Present Value (PV)

Now we calculate the present value (PV) of the company’s future cash flows. Since the company will likely reach full sales in 5 years, we’ll discount the future profits back to today’s value using the formula for present value:

PV = 540 million USD / (1 + 0.40)5

PV = 540 / (1.40)5 = 540 / 5.378 ≈ 100.4 million USD

7. Step 7: Estimate Exit Value and Ownership Dilution

The next step is to estimate the exit value, which is the potential market capitalization at the time of an exit (e.g., acquisition or IPO).

  • If we assume CEL-SCI is acquired or valued at 10 times its annual profit (which is a standard biotech exit multiple), the exit value would be:

    • Exit Value = 540 million × 10 = 5.4 billion USD

  • However, since the company will likely raise additional capital to fund operations, investors will experience ownership dilution. Let’s assume dilution of 50% due to future rounds of financing.

The post-dilution exit value for current investors would be:

Post-Dilution Exit Value = 5.4 billion × (1 – 50%) = 2.7 billion USD

8. Step 8: Calculate the Pre-Money Valuation

To calculate the pre-money valuation, we subtract the present value of future cash flows from the exit value:

Pre-Money Valuation = 2.7 billion USD – 100.4 million USD ≈ 2.6 billion USD

Conclusion

Using the Venture Capital Valuation Method, CEL-SCI Corporation (CVM) has an estimated potential valuation of $2.6 billion based on future cash flows from Multikine, adjusted for risk and dilution. However, this valuation is highly dependent on successful FDA approval and market penetration. Investors should consider the high-risk, high-reward nature of investing in clinical-stage biotech companies.